Patient Access

As affordability, access, and transparency reshape U.S. healthcare, manufacturers are rapidly redefining direct-to-patient drug distribution as a core strategic capability, one that demands fully integrated, data-driven platforms to secure control, competitiveness, and long-term value creation.

The FDA approves multiple new drugs, enhancing treatment options for cancer and other conditions.

The company is launching new self-pay pricing options, expanded savings programs, and partnerships with telehealth and retail providers. all while its obesity portfolio gains momentum under the FDA’s National Priority Voucher program.

As FDA fast-tracks GLP-1 treatments under its new pilot National Priority Voucher program, WeightWatchers prepares to position itself to compete in the fast-evolving weight-loss drug market driven by affordability and accessibility.

As the three models converge, expect a bigger role for sales reps, minimal impact on incentive compensation, and a boon to the healthcare system.

EMD Serono partners with the U.S. government to enhance IVF access, offering significant discounts on fertility treatments for millions of women.

Q&A with Harry Totonis, CEO and chairman of ConnectiveRx, on embracing change and seeking better solutions amid today’s challenging playing field for patient access.

Most Favored Nation drug pricing proposal aims to tie US medicine costs to lower European rates, but experts warn this approach could restrict patient access to lifesaving treatments, slow innovation, and jeopardize future drug development by importing flawed foreign price-control models.

The arrival of GLP-1 receptor agonists and dual agonists has delivered unprecedented efficacy, reframed obesity as a chronic disease, and sparked an industry gold rush.

The quest to align cost with care, enhance data visibility, and shed the dependence on outdated revenue streams.

Can deeper data from specialty pharmacy providers bolster both patient outcomes and financial returns?

The merger integrates EVERSANA’s commercialization services with Waltz Health’s AI-powered payer tools to address patient affordability, streamline drug access, and reduce costs for high-expense therapies such as GLP-1s.

Rob Abbott, CEO, ISPOR, highlights how emerging data strategies, advanced technology, and a renewed focus on patient needs are setting the direction for the next era of healthcare worldwide.

In this Pharmaceutical Executive exclusive, Bob Jansen, David Shulkin, Gen. Paul Funk (Ret.), and Maj. Gen. Dennis LeMaster (Ret.)—members of the Federated Healthcare Advisory Panel—discuss how pharmaceutical companies can strengthen supply chain resilience, navigate policy shifts, and adopt a national security mindset.

As the FDA’s ban on mass compounding of semaglutide takes effect, Novo Nordisk introduces discounted pricing and new patient resources to ensure safe access to Wegovy.

Country is poised to offer growth-channel opportunities for global pharma companies ready to scale access, innovation, and profitability.

The argument for weighing clinical points more heavily in the access equation.

Chip Parkinson, CEO, GiftHealth, explains how AI-powered data integration is bringing new hope to patients by revealing hidden access barriers, streamlining treatment pathways, and challenging outdated utilization management practices.

Tiara Green, president, Accessia Health, explains how empowering trusted local leaders and involving communities early are key to closing persistent gaps in preventive care and healthcare access.

Subject matter experts share the challenges that patients face in terms of medication affordability, along with the role that specialty pharmacies can play in helping to tackle these issues.

Will Pih, co-founder, Two Labs, explains how specialty pharmacies and manufacturers are adapting to financial pressures in rare disease care through patient-centric services, hub innovation, and hybrid technology models.

Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.

A panel of experts examines how stakeholders can support strategies that improve patient outcomes, while also navigating various distribution models.

Chip Parkinson, CEO, GiftHealth, explains how AI, real-time data, and closer payer collaboration are driving the next phase of growth and efficiency in specialty pharmacy.

Tiara Green, president, Accessia Health, highlights key themes from the upcoming discussion on how health equity, literacy, and social determinants are reshaping patient care—especially for those with chronic and rare conditions.